Survey reveals detrimental impact on organisational effectiveness and IT expenditure in healthcare and finance across the UK, France, Germany and the US.
GVK Biosciences (GVK BIO) and CRELUX announced today that they have set-up a highly robust fragment-based drug discovery platform proven to deliver rapidly, viable lead molecules. CRELUX’s high performance structural biology technologies together with GVK BIO’s mature computer-assisted drug design (CADD) tools and other components of its drug discovery and development engine, encompass all steps from challenging targets to novel drug candidates.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.